alexa Have FDA Expedited Programs Really Shortened Drug Review Time? An Analysis Of Newly Approved Therapies And How FDA Expedited Programs Have Impacted Drug Development Timelines | 19053
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Pharmaceutical Regulatory Affairs

Krasimira Pekova
Posters: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689.S1.015
Abstract
In attempt to encourage innovative drug development, the FDA hasdeveloped four programs to expedite the drug approval process for innovative or potential high-impact therapies. These four approaches include FastTrack, Breakthrough Therapy, Accelerated Approval and Priority Review. FastTrack was introduced to accelerate the approval of medications for serious conditions and to fulfill unmet medical need. Accelerated Approval is a pathway that permits medications for serious conditions that fulfill unmet medical need to receive approval based on a surrogate endpoint. Priority Review is designated for medications that when they get approved they will bring significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. Breakthrough therapy designation is anovel pathway introduced in 2012. Breakthrough therapy designation is intended to treat serious or life threatening disease. The objective of the research was to identify which of the expedited programs have truly shorteneddrug development time and which drugs and therapeutic areas have benefited the most from these programs. We analyzed new molecular entities that have been approved over the last 6 years (2009-2014) and determined which programs each entity was granted as they underwent regulatory review. We categorized the entitiesby therapeutic area, line of therapy and mechanism-specific order of entry. We then measured whether the expedited program the drug was granted had truly shortened the time from IND to regulatory approval.
Biography
Krasimira Pekova is a licensed pharmacist with experience in the healthcare industry in Europe and United States. She holds a pharmacy degree from Bulgaria and Master of Science in Regulatory Affairs of Drugs, Biologics and Medical Devices from Northeastern University, Boston, MA. Krasimira Pekovais an Analyst with Artisan Healthcare Consulting where she provides market access insights to global brands. She analyses the oncology global market access repository, a compilation of regulatory, health technology assessment, and reimbursement decisions for oncology products in the 15 largest markets worldwide. Artisan Healthcare Consulting is a management-consulting firm that provides strategic insights to healthcare product companies.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7